SynthesisSystematic reviews2025
Prognostic value of the pretreatment Naples prognostic score in gastrointestinal cancer patients: an updated meta-analysis with 28 studies.
Synthesis in Systematic reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe Naples prognostic score (NPS) has been extensively documented as a promising prognostic biomarker in various malignancies. The objective of this study is to systematically investigate the correlation between the pretreatment NPS and survival outcomes in patients with gastrointestinal (GI) cancer.
methodsThis meta-analysis was prospectively registered with PROSPERO (CRD42024567576). We conducted a systematic literature search using electronic databases, including Web of Science, PubMed, and Embase, from inception until July 1st, 2024. The primary endpoints assessed were long-term survival outcomes. Pooled hazard ratios (HR) with corresponding 95% confidence intervals (CI) were calculated using a random-effects model during the pooled analysis. Additionally, prediction intervals (PI) were generated to capture the variability of the pooled effect across different study settings.
resultsA total of 28 studies, including 10,874 patients with GI cancer, were included in this meta-analysis. The results unequivocally demonstrated a significant association between elevated NPS and worse OS, bolstered by the robust PIs. Moreover, the elevated NPS was found to be significantly related to poor DFS, while the evidence remained uncertain due to heterogeneous PIs. Additionally, findings from a single study suggested that a high NPS may be associated with poor CSS.
conclusionOur evidence suggests that the pretreatment NPS could be a valuable prognostic biomarker in GI cancer patients, particularly for OS. This information can be utilized by clinicians to stratify patients and develop personalized treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.